Evidence map›Paper›PMID 36430671›Full record

ReviewInternational journal of molecular sciences2022

Subclinical Acute Kidney Injury in COVID-19: Possible Mechanisms and Future Perspectives.

Rodrigo P Silva-Aguiar, Douglas E Teixeira, Rodrigo A S Peres, Diogo B Peruchetti, Carlos P Gomes, Alvin H Schmaier, Patricia R M Rocco, Ana Acacia S Pinheiro, Celso Caruso-Neves

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. O-GlcNAcylation in ischemic diseases.Frontiers in pharmacology · 2024
    Review
  7. Review
  8. Article
  9. Article
  10. Unmasking the presentation of AKD in COVID-19.Jornal brasileiro de nefrologia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Rodrigo P Silva-AguiarCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.ORCID 0000-0003-1975-8033
Douglas E TeixeiraCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.
Rodrigo A S PeresCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.
Diogo B PeruchettiCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.ORCID 0000-0002-7572-9731
Carlos P GomesClementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.
Alvin H SchmaierDepartment of Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.ORCID 0000-0002-3884-6234
Patricia R M RoccoCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.ORCID 0000-0003-1412-7136
Ana Acacia S PinheiroCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.ORCID 0000-0002-3894-1645
Celso Caruso-NevesCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.ORCID 0000-0002-2415-7753
Universidade Federal do Rio de Janeiro · BRUniversity Hospitals of Cleveland · US

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior CAPES/PRINT-88887.508141/2020-00Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/010.000983/2019Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/202.833/2017Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/202.950/2016Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/210.181/2020Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/211.139/2021National Council for Scientific and Technological Development 303793/2015-5National Council for Scientific and Technological Development 304682/2015-2National Council for Scientific and Technological Development 40.1700/2020-8National Council for Scientific and Technological Development 46.5656/2014-5
6 · The paper itself

Abstract

Since the outbreak of COVID-19 disease, a bidirectional interaction between kidney disease and the progression of COVID-19 has been demonstrated. Kidney disease is an independent risk factor for mortality of patients with COVID-19 as well as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leading to the development of acute kidney injury (AKI) and chronic kidney disease (CKD) in patients with COVID-19. However, the detection of kidney damage in patients with COVID-19 may not occur until an advanced stage based on the current clinical blood and urinary examinations. Some studies have pointed out the development of subclinical acute kidney injury (subAKI) syndrome with COVID-19. This syndrome is characterized by significant tubule interstitial injury without changes in the estimated glomerular filtration rate. Despite the complexity of the mechanism(s) underlying the development of subAKI, the involvement of changes in the protein endocytosis machinery in proximal tubule (PT) epithelial cells (PTECs) has been proposed. This paper focuses on the data relating to subAKI and COVID-19 and the role of PTECs and their protein endocytosis machinery in its pathogenesis.

Indexed as

Acute Kidney InjuryCOVID-19Renal Insufficiency, ChronicHumansKidney Tubules, ProximalSARS-CoV-2COVID-19kidney diseasemegalinproximal tubulerenal protein reabsorptionrenin-angiotensin system

Identifiers

PMID36430671
PMCPMC9693299
OpenAlexW4309608540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.